NCCN Breast Cancer Guidelines Updates 

Date: Thursday, April 18th 
Time: 12:00pm EST

Presenter: Gary Sopher, MBBCh, MSc Med, Medical Director, Breast/GYN Oncology, IM US Medical Affairs, Novartis Pharmaceutical

Description:  This presentation reviews the burden of breast cancer illness and the current NCCN Breast Cancer Guidelines in the HR+ HER2- metastatic setting. It will summarize  results from CDK 4/6 clinical trials which support the 2023 NCCN Guideline updates, reviewing the PALOMA, MONARCH and MONALEESA trials.  Additionally, it will describe clinical impact of the RIGHT CHOICE.  Lastly, it will summarize current cumulative clinical trial safety information into actionable patient counseling points for CDK 4/6 management.

Learning Objectives:
- Summarize recent NCCN Breast Cancer Guideline changes in the HR+ HER2- metastatic breast cancer space.
- Describe key CDK 4/6 clinical studies that led to the NCCN updates, including the PALOMA, MONARCH, MONALEESA trials. 

Target Audience: Health Care Practitioners and Clinicians
Fee: $0
CME/CE: 0 hours

Sponsored by: